Edotreotide yttrium Y-90

Star0

DB17160InvestigationalSmall molecule

Edotreotide yttrium Y-90: Overview.

Mechanism: Pharmacologically active on Somatostatin receptor
Curator reviewed
Formula / weight: C₆₅H₈₉N₁₄O₁₈S₂Y · 1508.53 g/mol (avg)
Also known as: 90y-dota-tyr3-octreotide · 90y-dotatoc · 90ydotatoc · Dotatoc yttrium Y-90 · Edotreotide 90y chelate
Code names: 90Y-SMT-487 · SMT-487 Y-90

Resolves to

Compound

UNIIABF7OG3FA3CAS322407-70-5

Structure

InChIKeyDUSFGVAHRFYHFD-LONMIUDCSA-KSMILES

[90Y+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Edotreotide yttrium Y-90, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account